Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Morpheus panBC umbrella study in metastatic hormone receptor-positive, HER2-negative breast cancer
MOH_2020-05-21_008822Phase 2Recruiting
- Sponsor
- Roche
- Start
- Mar 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of inavolisib, abemaciclib, ribociclib, fulvestrant and letrozole in breast cancer (4 arms), sponsored by Roche. Started Mar 2020; status: recruiting.
02
Drugs
inavolisibabemaciclibribociclibfulvestrantletrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on MOH_2020-05-21_008822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-05-21_008822.